ViroPharma Incorporated operates in the Pharmaceutical preparations sector. ViroPharma Incorporated (ViroPharma) is a global biotechnology company focused on the development and commercialization of products that address diseases, with a focus on products used by physician specialists or in hospital settings. The Company markets and sells Cinryze in the United States for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE). Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor (C1-INH) deficiency, a genetic disorder. It also markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the United States and its territories. In March 2010, the Company's Marketing Authorization Application (MAA) for Cinryze for acute treatment and prophylaxis against HAE was accepted by the European Medicines Agency (EMA). In November 2011, the Company announced that it completed its acquisition of DuoCort Pharma AB. In our complete report available for purchase the company is compared to: Medicines Company (The), Regeneron Pharmaceuticals Incorporated and Biomarin Pharmaceutical Inc.